Gossamer Bio Inc (NASDAQ:GOSS) has a beta value of 1.85 and has seen 1.49 million shares traded in the last trading session. The company, currently valued at $249.94M, closed the last trade at $1.10 per share which meant it lost -$0.07 on the day or -5.98% during that session. The GOSS stock price is -40.91% off its 52-week high price of $1.55 and 54.55% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.45 million shares traded. The 3-month trading volume is 1.44 million shares.
The consensus among analysts is that Gossamer Bio Inc (GOSS) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 10 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Sporting -5.98% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the GOSS stock price touched $1.10 or saw a rise of 16.03%. Year-to-date, Gossamer Bio Inc shares have moved 21.60%, while the 5-day performance has seen it change -14.06%. Over the past 30 days, the shares of Gossamer Bio Inc (NASDAQ:GOSS) have changed -10.57%. Short interest in the company has seen 5.74 million shares shorted with days to cover at 3.32.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 72.5% from current levels. The projected low price target is $2.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -354.55% off the targeted high while a plunge would see the stock gain -81.82% from current levels.
Gossamer Bio Inc (GOSS) estimates and forecasts
The company’s shares have gained 15.55% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -82.69%.
8 analysts offering their estimates for the company have set an average revenue estimate of 3.95M for the current quarter. 8 have an estimated revenue figure of 4.09M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.29% over the past 5 years. Earnings growth for 2025 is a modest -183.43% while over the next 5 years, the company’s earnings are expected to increase by 22.43%.
GOSS Dividends
Gossamer Bio Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
Insiders own 3.28% of the company shares, while shares held by institutions stand at 76.50% with a share float percentage of 79.09%. Investors are also buoyed by the number of investors in a company, with Gossamer Bio Inc having a total of 122.0 institutions that hold shares in the company. The top two institutional holders are NEA MANAGEMENT COMPANY, LLC with over 18.09 million shares worth more than $16.3 million. As of 2024-06-30, NEA MANAGEMENT COMPANY, LLC held 7.9979% of shares outstanding.
The other major institutional holder is ARTAL GROUP S.A., with the holding of over 13.31 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.99 million and represent 5.8832% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Jan 31, 2025 , the former fund manager holds about 3.48% shares in the company for having 7.91 shares of worth $8.71 million while later fund manager owns 6.76 shares of worth $7.44 million as of Dec 31, 2024 , which makes it owner of about 2.98% of company’s outstanding stock.
